Randomized, Multi-center, Double-blind, Placebo-controlled, Group-comparison Study to Investigate Safety, Tolerability and Pharmacodynamics of BAY2253651 After Administration of a Single Nasal Dose in 60 Subjects With Obstructive Sleep Apnea and Open Exploratory Evaluation of Safety and Local Tolerability of Repeated Doses in Patients
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs BAY-2253651 (Primary)
- Indications Sleep apnoea syndrome
- Focus Therapeutic Use
- Acronyms SANDMAN
- Sponsors Bayer
- 14 Nov 2019 This trial has been discontinued in Uk location.
- 24 Sep 2019 Status changed from active, no longer recruiting to completed.
- 26 Aug 2019 Planned End Date changed from 22 Jul 2019 to 27 Aug 2019.